
Sign up to save your podcasts
Or
How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Listen to hear what a rheumatologist should know about IBD!
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com
Disclosure: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Altomonte L, et al. Clin Rheumatol. 1994;13:565-570.
Dougados M, et al. Joint Bone Spine. 2011;78:598-603.
de Winter JJ, et al. Arthritis Res Ther. 2016;18:196.
El Miedany Y, et al. Am J Gastroenterol. 2006;101:311-317.
Long MD, et al. J Clin Gastroenterol. 2016;50:152-160.
Mayberry J. J Gastrointestin Liver Dis. 2013;22:375-377.
Miao X-P, et al. Curr Ther Res Clin Exp. 2008;69:181-191.
Mielants H, et al. J Rheumatol. 1995;22:2273-2278.
Morris AJ, et al. Lancet. 1991;doi: https://doi.org/10.1016/0140-6736(91)91300-J.
Redfern JS, Feldman M. Gastroenterology. 1989;96:596-605.
Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2006;4:203-211.
Stolwijk C, et al. Ann Rheum Dis. 2015;74:65-73.
Svartz N. Acta Medica Scandinavica. 1942;doi: https://doi.org/10.1111/j.0954-6820.1942.tb06841.x.
Takeuchi K, et al. Clin Gastroenterol Hepatol. 2006;4:196-202.
Tanaka K, et al. Eur J Pharmacol. 2008;603:120-132.
Van Praet L, et al. Ann Rheum Dis. 2013;72:414-417.
4.8
118118 ratings
How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Listen to hear what a rheumatologist should know about IBD!
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com
Disclosure: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Altomonte L, et al. Clin Rheumatol. 1994;13:565-570.
Dougados M, et al. Joint Bone Spine. 2011;78:598-603.
de Winter JJ, et al. Arthritis Res Ther. 2016;18:196.
El Miedany Y, et al. Am J Gastroenterol. 2006;101:311-317.
Long MD, et al. J Clin Gastroenterol. 2016;50:152-160.
Mayberry J. J Gastrointestin Liver Dis. 2013;22:375-377.
Miao X-P, et al. Curr Ther Res Clin Exp. 2008;69:181-191.
Mielants H, et al. J Rheumatol. 1995;22:2273-2278.
Morris AJ, et al. Lancet. 1991;doi: https://doi.org/10.1016/0140-6736(91)91300-J.
Redfern JS, Feldman M. Gastroenterology. 1989;96:596-605.
Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2006;4:203-211.
Stolwijk C, et al. Ann Rheum Dis. 2015;74:65-73.
Svartz N. Acta Medica Scandinavica. 1942;doi: https://doi.org/10.1111/j.0954-6820.1942.tb06841.x.
Takeuchi K, et al. Clin Gastroenterol Hepatol. 2006;4:196-202.
Tanaka K, et al. Eur J Pharmacol. 2008;603:120-132.
Van Praet L, et al. Ann Rheum Dis. 2013;72:414-417.
136 Listeners
323 Listeners
501 Listeners
124 Listeners
290 Listeners
3,339 Listeners
1,141 Listeners
115 Listeners
9 Listeners
190 Listeners
514 Listeners
31 Listeners
68 Listeners
30 Listeners
5 Listeners
15 Listeners
372 Listeners
181 Listeners
5 Listeners
13 Listeners
6 Listeners
5 Listeners
6 Listeners
18 Listeners